BRIUMVI shows lower disability progression vs competitors in MS study
TG Therapeutics (TGTX) published a study comparing BRIUMVI (ublituximab-xiiy) with competitors ocrelizumab and ofatumumab in relapsing multiple sclerosis patients. The analysis showed BRIUMVI had a 44% lower disability progression hazard vs. ocrelizumab and 49% lower vs. ofatumumab. The study was funded by Neuraxpharm, TG's European partner.
How this was made
The 30-second read
Why it matters
The new comparative data may shift investor expectations for TG Therapeutics and its peers, potentially affecting stock valuations.
Market read
First report of a head‑to‑head efficacy advantage for BRIUMVI, likely to influence biotech market sentiment.
What to watch
Reimbursement negotiations and pricing could moderate the commercial impact despite clinical advantage.
Background
BRIUMVI (ublituximab-xiiy) is TG Therapeutics' FDA‑approved monoclonal antibody for relapsing multiple sclerosis.
Ticker impact
TG Therapeutics released a new indirect comparison showing its BRIUMVI drug has significantly lower disability progression versus ocrelizumab and ofatumumab.
likely upward pressure as investors price in superior efficacy.
The study reports 44-49% lower hazard of disability progression, a material advantage that could boost sales expectations.
Market effects
May improve outlook for the MS therapeutic segment and increase competitive pressure on ocrelizumab and ofatumumab makers.
Potentially boosts US biotech sentiment, especially for companies with FDA‑approved MS drugs.
Could influence global MS treatment markets as BRIUMVI is approved in multiple regions.
Counterpoint
The indirect comparison methodology has limitations; results may not translate to real‑world superiority.
Key entities
- companyTG Therapeutics Inc.
Developer of BRIUMVI, a multiple sclerosis therapy.
- drugBRIUMVI
Ublituximab-xiiy, an MS treatment.
